The global angina pectoris treatment market is anticipated to gain impetus from the increasing awareness programs regarding the availability of several therapy options. Fortune Business Insights, in an upcoming report, titled, “Angina Pectoris Treatment Market Size, Share and Global Trend By Drug Class (Beta Blockers, Calcium Antagonists, Anti-coagulants, Anti-Platelets), Disease Type (Stable or chronic angina, Unstable angina, Variant and microvascular angina), Distribution Channel (Online pharmacies, Hospital pharmacies, Retail pharmacies) and Geography Forecast till 2026,” rising per capita healthcare spending, availability of personalized medicine, and surge in the economies are expected to boost the global angina pectoris treatment market growth in the coming years. Moreover, a rising number of upcoming pipelines for potential candidates will also contribute to growth.
Get Sample PDF Brochure at
Top Leaders Overview:
Some of the leading companies in the global Angina Pectoris Treatment Market are
- Bayer AG
- Bristol-Myers Squibb
- Hoffmann-La Roche Ltd
- Gilead Sciences
- GlaxoSmithKline Pharma GmbH
- Sanofi and other key players.
The report offers global angina pectoris treatment market share assessment for the country as well as regional level segments. It further provides strategic recommendations for the new entrants in the market. Furthermore, the report aids in providing supply chain trends by mapping the ongoing technological advancements.
By Drug Class
- Calcium Antagonists
By Disease Type
- Stable or chronic angina
- Unstable angina
- Variant and microvascular angina
By Distribution Channel
- Online pharmacies
- Hospital pharmacies
- Retail pharmacies
New Innovative Product Launches to Favor Growth in North America
The global angina pectoris treatment market is geographically divided into Latin America, Asia Pacific, Europe, the Middle East and Africa, and North America. Out of these, North America is projected to lead the global market during the forecast period. It would occur due to the introduction of several guidelines involved in managing and diagnosing patients suffering from stable ischemic heart disease.
New product launches also contribute to the growth in this region. Asia Pacific, on the other hand, is considered to remain in the second-fastest-growing market due to the rising economies in the healthcare sector.
Janssen Receives FDA Approval for its Rivaroxaban (Xarelto) to Expand its Usage
In October 2018, the FDA officials declared its approval for Janssen’s rivaroxaban (Xarelto). The oral anticoagulant was first approved in 2011. It is now meant to reduce the risk of acute cardiovascular (CV) events, namely, stroke, myocardial infarction (MI), and death in those with chronic peripheral or coronary artery disease (PAD/CAD). FDA approval makes rivaroxaban the only Factor Xa inhibitor that is for the patients suffering from these conditions. Janssen is a renowned pharmaceutical company based in Belgium.
In spite of the usage of guideline-recommended therapies, sufferers of chronic PAD or CAD are at high risk of having an irreversible and devastating CV event. The latest Xarelto vascular 2.5mg dose is to bed used with aspirin. It represents a breakthrough for patients with chronic PAD and CAD.
Browse Complete Report Details at
AstraZeneca Enters into Strategic Collaboration with Recordati to Deliver Seloken in Europe
AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, headquartered in the U.K., announced that it has partnered up with Recordati, an Italy-based pharmaceutical company in May 2017. The main of the collaboration is to gain commercial rights to Seloken ZOK (metoprolol succinate) and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate aids in controlling heart failure, angina, and hypertension. AstraZeneca received a payment of USD 300 from Recordati after the completion of this partnership. AstraZeneca will develop and supply the medicines to the latter under another supply agreement. Product sales for Logimax and Seloken brands were USD 100 million in Europe, in 2016. AstraZeneca will commercialize these medicines in all the markets where it holds the rights.
STRONG INDUSTRY FOCUS:
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
More Trending Topics from Fortune Business Insights:
Why the Neuroendocrine Tumors Treatment Market is set to explode? Top Companies: Novartis, Pfizer, Ipsen Pharma GmbH, Advanced Accelerator Applications, Tarveda Therapeutics and more